BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024

Core Insights - BridgeBio Pharma, Inc. announced additional data on clinical outcomes from its Phase 3 study of acoramidis in ATTR-CM, to be presented at two major upcoming medical conferences [1][2] Group 1: Clinical Study and Presentations - The Phase 3 study, ATTRibute-CM, focuses on the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) with acoramidis [1] - Presentations will occur at the European Society of Cardiology (ESC) Congress 2024 in London from August 30 to September 2, and at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024 in Atlanta from September 27 to 30 [1][2] - Dr. Mathew S. Maurer will present findings on serum TTR levels observed with acoramidis treatment at the ESC Congress [2] - Dr. Daniel P. Judge will present a post hoc recurrent event analysis of clinical outcomes at the HFSA meeting [2] Group 2: Company Overview - BridgeBio Pharma is a commercial-stage biopharmaceutical company focused on developing transformative medicines for genetic diseases [3] - The company was founded in 2015 and has a pipeline that includes programs from early science to advanced clinical trials [3] - BridgeBio aims to leverage advances in genetic medicine to expedite treatment for patients [3]